| 商品名称 | Kiovig |
|---|
| 适用类别 | Human |
|---|
| 治疗领域 | Purpura, Thrombocytopenic, Idiopathic;Bone Marrow Transplantation;Immunologic Deficiency Syndromes;Guillain-Barre Syndrome;Mucocutaneous Lymph Node Syndrome |
|---|
| 通用名/非专利名称 | human normal immunoglobulin |
|---|
| 活性成分 | human normal immunoglobulin (IVIg) |
|---|
| 产品号 | EMEA/H/C/000628 |
|---|
| 患者安全信息 | No |
|---|
| 许可状态 | Authorised |
|---|
| ATC编码 | J06BA02 |
|---|
| 是否额外监管 | No |
|---|
| 是否仿制药或hybrid药物 | No |
|---|
| 是否生物类似药 | No |
|---|
| 是否附条件批准 | No |
|---|
| 是否特殊情形 | No |
|---|
| 是否加速审评 | No |
|---|
| 是否罕用药 | No |
|---|
| 上市许可日期 | 2006/01/19 |
|---|
| 上市许可开发者/申请人/持有人 | Takeda Manufacturing Austria AG |
|---|
| 人用药物治疗学分组 | Immune sera and immunoglobulins |
|---|
| 兽用药物治疗学分组 | |
|---|
| 欧盟委员会决定日期 | 2022/06/24 |
|---|
| 修订号 | 26 |
|---|
| 治疗适应症 | Replacement therapy in adults, and children and adolescents (0-18 years) in: primary immunodeficiency syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed; hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation; hypogammaglobulinaemia in patients after allogeneic haematopoietic-stem-cell transplantation (HSCT); congenital AIDS and recurrent bacterial infections. Immunomodulation in adults, and children and adolescents (0-18 years) in: primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count; Guillain Barré syndrome; Kawasaki disease; multifocal motor neuropathy (MMN). |
|---|
| 适用物种 | |
|---|
| 兽用药物ATC编码 | |
|---|
| 首次发布日期 | 2017/06/07 |
|---|
| 最后更新日期 | 2022/06/27 |
|---|
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/kiovig-epar-product-information_en.pdf |
|---|
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/kiovig |
|---|